Big Phar­ma VCs jump in to back a $63M mis­sion to tack­le a ge­net­ic dri­ver of Alzheimer’s

About five years ago a pair of sci­en­tists at the Glad­stone In­sti­tutes — Robert Mahley and Yadong Huang — had seen enough clin­i­cal fail­ures in Alzheimer’s drug re­search to urge a change in strat­e­gy. If the clas­sic ap­proach on leech­ing amy­loid-be­ta out of the brain was pro­duc­ing on­ly colos­sal fail­ure, they said, why not ze­ro in on a key ge­net­ic trig­ger linked to a well-de­fined risk of de­vel­op­ing the dis­ease?

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.